Does clinical benefit of ipatasertib outweigh risk for adverse events?

Posted on September 21, 2020 by Sitemaster

Roche/Genentech’s investigational drug ipatasertib has demonstrated a small but statistically significant benefit in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) who had tumors exhibiting loss of the phosphatase and tensin (PTEN) homolog: a 2-month improvement in median radiographic progression-free survival (rPFS). … READ MORE …

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , | 7 Comments »

Ipatasertib meets one of two primary endpoints in Phase III trial

Posted on June 19, 2020 by Sitemaster

According to a media release issued by Roche earlier this morning, the company’s investigational drug known as ipatasertib met one but not both of the two primary endpoints in a randomized, double-blind Phase III trial known as the IPATential150 trial. … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , , , | Leave a comment »

  • Donate

  • Disclaimer

    News and information provided on this site should not be used for diagnosing or treating any health problem or disease.

    The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.

  • Hot Posts …

  • … and Archives